ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. - Wikidata - wikimedia - TriplyDB

ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.

ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.

http://www.wikidata.org/entity/Q30474678

about

Neurofibromatosis type 2 protein, NF2: an uncoventional cell cycle regulator.A neuronal function of the tumor suppressor protein merlin Development of drug treatments for neurofibromatosis type 2-associated vestibular schwannoma.p75NTR is highly expressed in vestibular schwannomas and promotes cell survival by activating nuclear transcription factor κB.Inhibition of c-Jun N-terminal kinase activity enhances vestibular schwannoma cell sensitivity to gamma irradiation.Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms ErbB expression, activation, and inhibition with lapatinib and tyrphostin (AG825) in human vestibular schwannomas.Treatment of vestibular schwannoma cells with ErbB inhibitors Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas.AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.The molecular biology of vestibular schwannomas and its association with hearing loss: a review.Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas Kindlins, integrin activation and the regulation of talin recruitment to αIIbβ3.Neurofibromatosis-related tumors: emerging biology and therapies.Role of Merlin/NF2 inactivation in tumor biology.Contemporary management of acoustic neuromas.Emerging therapeutic targets in schwannomas and other merlin-deficient tumors.Merlin, a multi-suppressor from cell membrane to the nucleus.Advances in the treatment of neurofibromatosis-associated tumours.Schwannomas and their pathogenesis.YAP Mediates Tumorigenesis in Neurofibromatosis Type 2 by Promoting Cell Survival and Proliferation through a COX-2-EGFR Signaling Axis.The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma.Gastric plexiform schwannoma in association with neurofibromatosis type 2.Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours.Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannoma proliferation, adhesion and survival.The role of insulin-like growth factors signaling in merlin-deficient human schwannomas.Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival.An update on the diagnosis and treatment of vestibular schwannoma.Back to the future: proceedings from the 2010 NF Conference.Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.Pathogenesis and management of type 2 neurofibromatosis Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2

P2860

Q26825296-D268E22C-D6CA-408E-A971-ABC98B53E27E Q26830181-DCB70337-5229-43D5-ADFC-6188E9043E1A Q30389069-1C870C2E-64F6-454F-88DC-6AC5D2AC8219 Q30401833-0A210FDF-AA77-4D8C-9248-2EE6C039A7B3 Q30419586-C3A7D727-FED5-4330-93C4-EDBCF6B31FC2 Q30450038-45EE4F2B-2D7F-4AF1-AF29-FBDF2ECBEB4E Q30457681-11B0FDE4-3094-462C-A97B-1075DDC512D4 Q30457869-90A80F86-B8DE-4616-BABF-70F30CB73FDE Q30458767-E537FC36-E59B-466B-AC23-B30D42110F3E Q30459589-53657C4D-70A7-424F-BE44-504818DC7B85 Q30464276-7D27A53A-4D79-4C8F-A461-C12E3AAD06F5 Q30467803-19168300-9409-4B7E-87CC-5EC1EA2BC76C Q34062012-1E2A09DE-808B-4279-8449-AF70C9373084 Q34212141-E5271C92-721F-47FA-847F-E3FA9EE028C2 Q35218073-DD9CE25A-7774-41A1-AF5C-5DD0EBAB6B2B Q36189820-D6B6FEAE-77F7-4D9E-981C-306BD57D760A Q37873874-4BAB03C1-08EF-4168-9E76-87A66FF7C92F Q37885731-16A52C9A-9433-4E36-BEB3-ECC9B594E4B5 Q38010858-6C423BFB-40E1-41A8-9684-442478113173 Q38128516-22DF313A-E217-4C4B-BE6E-7F3F99CDC083 Q38180808-979C3FFF-8F2A-4605-8D86-C06A82362398 Q38437859-441142D4-4B70-4D20-A322-69E0B0105A7E Q38666243-A853BAD9-4806-475F-8388-101F4208548F Q38970548-93DB05CD-D963-4EAA-AA7D-735753496F95 Q39512836-DD908DA9-08AD-4BFF-A8FA-231E4ABB9103 Q41135859-F217DE02-20B4-464E-B4C1-A706E885A148 Q42223215-01A36BAA-5FED-4BE3-BF7C-6C53B909A650 Q42493873-DFB9546A-B6A5-4364-9146-12A8CB00F789 Q42509945-6EE5171A-3870-4357-8DC3-2505217CF3BD Q46412577-A1951D32-9C62-4A60-8409-3E2745DB71DD Q47681038-CB8F698D-20A4-4C59-810C-9DA31A483414 Q55130390-AC867F5C-8EC9-4441-976D-DF13D8C96334 Q55383186-B39B16C0-AE20-4EA0-BF5E-C631243052FF Q55638662-D577887D-B298-4685-BAFA-113F63C19B9E Q57266478-A170A190-C1DD-461C-89B7-1BF738FE0FC0 Q57266579-C325F8A9-9796-47B5-9E8C-4B029623AF15

P2860

ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.

http://www.wikidata.org/entity/Q30474678

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

ErbB/HER receptor activation a ...... inib in vestibular schwannoma.

@ast

ErbB/HER receptor activation a ...... inib in vestibular schwannoma.

@en

type

label

ErbB/HER receptor activation a ...... inib in vestibular schwannoma.

@ast

ErbB/HER receptor activation a ...... inib in vestibular schwannoma.

@en

prefLabel

ErbB/HER receptor activation a ...... inib in vestibular schwannoma.

@ast

ErbB/HER receptor activation a ...... inib in vestibular schwannoma.

@en

P1433

Q30474678-A40C50D5-84C8-4D78-8D69-E3E013AA54D3

P1476

Q30474678-8BF94CAD-E2D1-4299-8E08-9DADCF69B40E

P2093

Q30474678-2D522799-5574-4EB6-948E-3251A27D0BF3

Q30474678-2EBFB523-7D2F-4B38-86CA-DAADE52304D4

Q30474678-520A8E7C-C847-446E-8CD3-FE45CF7C30AD

Q30474678-6B0DF0F5-2A31-4CAF-9092-3D803A41021C

Q30474678-A992D562-5BC6-40CF-AD4C-5465631CB4C0

Q30474678-B2E03F64-EE06-402B-AA00-DCD835C78DAB

Q30474678-F96F2FA2-FA4E-4219-9ED0-C4ED06508912

Q30474678-FC335BCB-5F43-4D78-9D77-4761AB8582A5

P2860

Q30474678-0CF99C6C-3E6B-487E-ADCC-2B5B891DB35C

Q30474678-211C2C7B-E415-43D7-A531-5167C1F102D2

Q30474678-29E428B6-41E2-4ED7-AE3C-59E070B5FF12

Q30474678-2DA04453-F834-4024-BC54-3C3052AF1FBD

Q30474678-31C9AA55-D302-44D4-BD0D-1146D135E464

Q30474678-3489DE0A-689B-43E7-8139-0EBF57AA1B5D

Q30474678-37424E2C-732F-423E-9881-7CCE9C7116D0

Q30474678-3C17A28F-44E0-4351-B640-AE8CB02B9B2E

Q30474678-3EDE45FB-44B0-47A2-8D69-14AD9E613777

Q30474678-460C4741-FF87-4DB9-A768-AE6566D07FCD

P304

Q30474678-B38E3DAA-0D30-47EB-88AB-EAAF0BF57A78

P31

Q30474678-E2ADE02C-A69F-4B81-BCB6-105D3C945F10

P356

Q30474678-BE5FC11D-823B-4BE5-9715-66F0F363D206

P433

Q30474678-CCEC770B-0467-408C-B0A8-A75A95D38658

P478

Q30474678-4C73CB18-017B-4715-ABF6-B203A9328938

P577

Q30474678-64D555F5-F466-4CBF-B645-7427EAE0A225

P5875

Q30474678-2072B1ED-BEDD-4E13-862B-ADA82E35371B

P698

Q30474678-D57C27F1-9A7F-4B50-9FC3-B34BF0EE0002

P932

Q30474678-0CAF4728-392F-4CC0-A2CE-C19004DD3207

P356

P1433

P1476

ErbB/HER receptor activation a ...... inib in vestibular schwannoma.

@en

P2093

C Oliver Hanemann

http://www.w3.org/2001/XMLSchema#string

Clare H Cunliffe

http://www.w3.org/2001/XMLSchema#string

David Zagzag

http://www.w3.org/2001/XMLSchema#string

Filippo G Giancotti

http://www.w3.org/2001/XMLSchema#string

Jeffrey C Allen

http://www.w3.org/2001/XMLSchema#string

Luis Chiriboga

http://www.w3.org/2001/XMLSchema#string

Matthias A Karajannis

http://www.w3.org/2001/XMLSchema#string

Sylwia Ammoun

http://www.w3.org/2001/XMLSchema#string

P2860

Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2

The soluble sema domain of the RON receptor inhibits macrophage-stimulating protein-induced receptor activation

The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer

Neuregulin-1, a key axonal signal that drives Schwann cell growth and differentiation

Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling.

The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study

Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas.

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.

RON, a tyrosine kinase receptor involved in tumor progression and metastasis.

Contact-dependent inhibition of EGFR signaling by Nf2/Merlin

P304

834-843

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NEUONC/NOQ012

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44638648

http://www.w3.org/2001/XMLSchema#string

P698

20511180

http://www.w3.org/2001/XMLSchema#string

P932

2940674

http://www.w3.org/2001/XMLSchema#string